Can-Fite BioPharma Ltd. CANF
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $405,000, -39.9% YoY · Filed Mar 26, 2026
Can-Fite BioPharma Ltd. (CANF) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $405,000 and a net loss of $9.8 million. Free cash flow was -$9.0 million. As of Dec 31, 2025 it held $5.5 million in cash and investments and $71,000 in total debt.
Revenue
$405,000
-39.9% vs prior year
Net income
$-9.83M
-24.7% vs prior year
Operating cash flow
$-8.95M
-17.2% vs prior year
Free cash flow
$-8.95M
-17.1% vs prior year
EPS
$-5.97
+45.0% vs prior year
Dividend per share
None
Shares outstanding
2.62M
-99.9% vs prior year
Net cash
$5.46M
FY 2025
Operating margin
-2456.8%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CANF (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1536196
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $405,000 | $674,000 | $743,000 | $810,000 | $853,000 |
| Operating income | -$9.9M | -$8.1M | -$8.2M | -$10.1M | -$12.8M |
| Net income | -$9.8M | -$7.9M | -$7.6M | -$10.2M | -$12.6M |
| Diluted EPS | -$5.97 | -$10.86 | -$17.92 | -$0.01 | — |
| Operating cash flow | -$8.9M | -$7.6M | -$8.4M | -$10.8M | -$9.9M |
| Free cash flow | -$9.0M | -$7.6M | -$8.4M | -$10.8M | -$9.9M |
| Total assets | $9.5M | $9.1M | $10.0M | $9.3M | $20.3M |
| Stockholders' equity | $5.6M | $5.4M | $6.2M | $4.5M | $14.4M |
| Cash and investments | $5.5M | $4.8M | $4.3M | $3.0M | $4.6M |
| Total debt | $71,000 | $104,000 | $40,000 | $62,000 | $124,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 26, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 3, 2026 | Sep 3, 2026 |
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 2, 2026 |
All 865 Can-Fite BioPharma Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.